Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc
AGNPF
Primary Symbol:
C.AGN
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(75)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Apr 03, 2023 6:07pm
AGN to raise money for AGN Neuro subsidiary
Algernon NeuroScience, a wholly owned subsidiary of Algernon Pharmaceuticals (AGN.c AGNPF) has qualified its Form 1-A offering statement filed with the U.S. Securities and Exchange Commission under a
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 03, 2023 7:00am
New Press Release - Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary...
read article.
C.RVV Announces Type C Meeting Request Granted by FDA for Clinical Study
posted Apr 24, 2024 9:00am by
Revive Therapeutics Ltd.
-
|
Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA ...read more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Apr 02, 2023 10:30pm
AP Loves The Thrill Of The Hunt Way More Than Kill-er Data
I don't see (understand) where anything prevents those eligible for the Rights Offering from buying and dumping existing stock. Canadian shareholders are literally on the verge of determining
...more
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Post by
Whalewatcher1
on Mar 31, 2023 9:38pm
Why would anyone purchase their rights offering?
Looking at this rights offering closer, If 100% is subscribed, $2.2M comes in ($2.4M – 0.2M fees). They had $1.9M working capital deficiency as of Feb 28 2023 as per Rights offering doc.
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Mar 30, 2023 7:11pm
RE:RE:RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA
Dunno. I report. You decide. What I'd surmise at first glance is Williams likely held back what he'd consider his best repurposed drug candidate for himself. Of all the repurposed drug
...more
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Comment by
Whalewatcher1
on Mar 30, 2023 7:09pm
RE:RE:Upcoming Work
And don't forget these guys are more interested in promoting the stock by using cash on marketing and not drug development. Someone should tell them that marketing comes after approval hahah
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Comment by
Whalewatcher1
on Mar 30, 2023 6:31pm
RE:RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA
The so called Dr Williams is doing the same so called "repurposing" pitch at marvel bioscience. Looks like they also are alimony out of cash. Who's going to be holding the bag in these
...more
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Comment by
Whalewatcher1
on Mar 30, 2023 6:24pm
RE:Upcoming Work
So how will these clinical trials be finding when the company has over $2M in payables and no Cdh based on financial statements. They are doing a rights offering that likely won't even cover the
...more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Mar 30, 2023 2:14pm
Upcoming Work
AGN.c AGNPF is currently undergoing clinical studies and the results could be a major catalyst if they’re successful. Some of their upcoming work includes - Have a 180 patient, 90-day Phase 2b
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Mar 29, 2023 8:50am
10 years to steer the last company into insolvency
Now it's taken your CEO only 5 years.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Mar 29, 2023 2:48am
RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA
Further clarification for the slow one here. Maybe this will send him back to whatever cave he crawled out of these days? However, he'll likely have a so-called opinion about something else he
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Mar 29, 2023 2:40am
RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA
Wrong as usual but don't let that stop you from trolling all over again. Also, who cares about arch? if anyone reads that board they'll see where your hype and river dances is complete
...more
(5)
•••
TheBearInTheWoods
X
View Profile
View Bullboard History
Comment by
TheBearInTheWoods
on Mar 28, 2023 11:18pm
RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA
You are still in this dog lmao, ARCH was just given the market cap or AGN in a gov grant for a NEW mechanism of action.
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Post by
Whalewatcher1
on Mar 28, 2023 7:58pm
Trading starting March 29th will be interesting
Shouldnt the stock be trading well below $0.25? if current shareholders can buy the rights offering for $0.25 an get a warrant, won't every current investor be selling at below $0.25? will
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Mar 28, 2023 7:33pm
RE:Interview with CEO on Upcoming Clinical Trial
Man these bots post up some dumb down stuff. The video attached is from 2 months ago. Is it that hard to see they have NO MONEY to run a Chronic Cough trial or any trial? What money they'll
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Discover a Green Resources Stock Scoring Record Quarterly Growth
Stage Set for Creation of a Leading Intermediate Gold Producer